

Marc Fishman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/844358/publications.pdf>

Version: 2024-02-01

30
papers

1,335
citations

567281

15
h-index

454955

30
g-index

33
all docs

33
docs citations

33
times ranked

1329
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapy Dose Mediates the Relationship Between Buprenorphine/Naloxone and Opioid Treatment Outcomes in Youth Receiving Medication for Opioid Use Disorder Treatment. <i>Journal of Addiction Medicine</i> , 2022, 16, e97-e104.	2.6	4
2	Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapse. <i>Addiction</i> , 2022, 117, 637-645.	3.3	4
3	Towards an International Consensus on the Prevention, Treatment, and Management of High-Risk Substance Use and Overdose among Youth. <i>Medicina (Lithuania)</i> , 2022, 58, 539.	2.0	5
4	Co-occurring Depression and Suicidal Ideation in Opioid Use Disorder. <i>Journal of Clinical Psychiatry</i> , 2022, 83, .	2.2	3
5	Mobile van delivery of extended-release buprenorphine and extended-release naltrexone for youth with OUD: An adaptation to the COVID-19 emergency. <i>Journal of Substance Abuse Treatment</i> , 2021, 120, 108149.	2.8	18
6	A pilot randomized controlled trial of assertive treatment including family involvement and home delivery of medication for young adults with opioid use disorder. <i>Addiction</i> , 2021, 116, 548-557.	3.3	21
7	Youth OUD treatment during and after COVID: Increasing family involvement across the services continuum. <i>Journal of Substance Abuse Treatment</i> , 2021, 120, 108159.	2.8	11
8	Opioid overdose experiences in a sample of US adolescents and young adults: a thematic analysis. <i>Addiction</i> , 2021, 116, 865-873.	3.3	13
9	Conceptual framework for telehealth strategies to increase family involvement in treatment and recovery for youth opioid use disorder. <i>Journal of Marital and Family Therapy</i> , 2021, 47, 501-514.	1.1	10
10	Examination of Correlates of OUD Outcomes in Young Adults: Secondary Analysis From the XBOT Trial. <i>American Journal on Addictions</i> , 2021, 30, 433-444.	1.4	4
11	Choice of extended release medication for OUD in young adults (buprenorphine or naltrexone): A pilot enhancement of the Youth Opioid Recovery Support (YORS) intervention. <i>Journal of Substance Abuse Treatment</i> , 2021, 125, 108306.	2.8	5
12	Family involvement in treatment and recovery for substance use disorders among transition-age youth: Research bedrocks and opportunities. <i>Journal of Substance Abuse Treatment</i> , 2021, 129, 108402.	2.8	31
13	Treatment Trajectories During and After a Medication Trial for Opioid Use Disorder: Moving from Research as Usual to Treatment as Usual. <i>Journal of Addiction Medicine</i> , 2020, 14, 331-336.	2.6	10
14	Young Adults Have Worse Outcomes Than Older Adults: Secondary Analysis of a Medication Trial for Opioid Use Disorder. <i>Journal of Adolescent Health</i> , 2020, 67, 778-785.	2.5	20
15	Medication Treatment for Opioid-Addicted Youth—What Are We Waiting for?. <i>Journal of Adolescent Health</i> , 2020, 67, 9-10.	2.5	5
16	A Motion-Activated Video Game for Prevention of Substance Use Disorder Relapse in Youth: Pilot Randomized Controlled Trial. <i>JMIR Serious Games</i> , 2019, 7, e11716.	3.1	7
17	Buprenorphine Treatment for Adolescents and Young Adults With Opioid Use Disorders: A Narrative Review. <i>Journal of Addiction Medicine</i> , 2018, 12, 170-183.	2.6	45
18	Home-based delivery of XR-NTX in youth with opioid addiction. <i>Journal of Substance Abuse Treatment</i> , 2018, 85, 84-89.	2.8	14

#	ARTICLE	IF	CITATIONS
19	Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. <i>Lancet, The</i> , 2018, 391, 309-318.	13.7	502
20	Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. <i>New England Journal of Medicine</i> , 2016, 374, 1232-1242.	27.0	255
21	Relapse Prevention Medications in Community Treatment for Young Adults with Opioid Addiction. <i>Substance Abuse</i> , 2016, 37, 392-397.	2.3	22
22	NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale. <i>Contemporary Clinical Trials</i> , 2016, 50, 253-264.	1.8	49
23	Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence. <i>Contemporary Clinical Trials</i> , 2016, 51, 34-43.	1.8	28
24	Opioid Use Disorders. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2016, 25, 473-487.	1.9	78
25	Polysubstance Use and Heroin Relapse Among Adolescents Following Residential Treatment. <i>Journal of Child and Adolescent Substance Abuse</i> , 2012, 21, 204-221.	0.5	9
26	Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth. <i>Addictive Behaviors</i> , 2012, 37, 1046-1053.	3.0	55
27	Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone. <i>Addiction</i> , 2008, 103, 1399-1401.	3.3	37
28	Clinical Characteristics and Treatment Outcomes of Adolescent Heroin Users. <i>Journal of Psychoactive Drugs</i> , 2004, 36, 85-94.	1.7	25
29	Mood disorders in HIV infection. <i>Depression and Anxiety</i> , 1998, 7, 178-187.	4.1	41
30	Mood disorders in HIV infection. <i>International Review of Psychiatry</i> , 1996, 8, 267-276.	2.8	3